DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib

First Posted Date: 2021-12-17

Last Posted Date: 2021-12-17

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT05161143

Locations: 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China

Application Registration Study of ILE in Patients With Acute Poisoning

Not yet recruiting

Conditions: Acute Poisoning

First Posted Date: 2021-12-08

Last Posted Date: 2021-12-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 500

Registration Number: NCT05148611

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Phase 2

Conditions: Gestational Trophoblastic Neoplasia

Interventions: Drug: Camrelizumab plus apatinib CohortA
Drug: Camrelizumab plus apatinib Cohort B

First Posted Date: 2021-12-01

Last Posted Date: 2022-07-11

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 73

Registration Number: NCT05139095

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Phase 4

Not yet recruiting

Conditions: Thrombotic Thrombocytopenic Purpura, Acquired

Interventions: Drug: Bortezomib Injection

First Posted Date: 2021-11-26

Last Posted Date: 2021-11-26

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT05135442

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, (Select), China

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Completed

Conditions: Chronic Periaortitis
Tocilizumab Monotherapy

Interventions: Drug: Tocilizumab monotherapy

First Posted Date: 2021-11-24

Last Posted Date: 2023-03-02

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 12

Registration Number: NCT05133895

Locations: 🇨🇳
Yunyun Fei, Beijing, China

Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT

Phase 1

Recruiting

Conditions: Pulmonary Fibrosis

Interventions: Drug: 68Ga-FAPI
Drug: 18F-FDG

First Posted Date: 2021-11-16

Last Posted Date: 2024-11-25

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 80

Registration Number: NCT05121779

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

To Evaluate the Efficacy and Safety of ABCD in the Treatment of IFD

Recruiting

Conditions: Invasive Fungal Disease

First Posted Date: 2021-11-10

Last Posted Date: 2022-10-21

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 500

Registration Number: NCT05116059

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Comparison Between Home-based Wearable Device and Supervised PFMT on SUI/MUI

Not Applicable

Completed

Conditions: Stress Urinary Incontinence

Interventions: Device: PFMT with device

First Posted Date: 2021-11-10

Last Posted Date: 2024-11-21

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 500

Registration Number: NCT05115864

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Neuroendocrine Tumor Grade 3
Neuroendocrine Carcinoma
Neuroendocrine Neoplasm

Interventions: Drug: Chidamide
Drug: Sintilimab

First Posted Date: 2021-11-09

Last Posted Date: 2021-11-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 23

Registration Number: NCT05113355

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

The Study of Regional Lung Ventilation-perfusion by EIT

Conditions: Pulmonary Perfusion
Pulmonary Ventilation

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-03

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT05105932

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy